{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:43:42Z","timestamp":1794469422810,"version":"4.9.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ygyno.2024.03.009","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T17:25:16Z","timestamp":1717435516000},"page":"128-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Efficacy and safety of niraparib in patients aged 65\u00a0years and older with advanced ovarian cancer: Results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial"],"prefix":"10.1016","volume":"187","author":[{"given":"Giorgio","family":"Valabrega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney S.","family":"Graybill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Baurain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V.","family":"Tinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelore","family":"Denys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin E.","family":"O\u2019Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakari","family":"Hietanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja \u00d8r","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"de La Motte Rouge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Heitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tally","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"York","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.03.009_bb0005","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1186\/s12885-019-6139-6","article-title":"Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0010","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int. J. Women's Health"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0015","series-title":"SEER cancer Statistics Review, 1975\u20132017","author":"Howlader","year":"2020"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0020","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cncr.2820710218","article-title":"Age as a prognostic factor in ovarian carcinoma: the Gynecologic Oncology Group experience","volume":"71","author":"Thigpen","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0025","first-page":"227","article-title":"Treatment and trials: ovarian cancer in older women","volume":"33","author":"Freyer","year":"2013","journal-title":"ASCO Education Book"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2016.03.018","article-title":"Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: results of a pooled analysis of three GINECO phase II trials","volume":"143","author":"Tinquaut","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0040","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2016.00063","article-title":"The application and outcome of standard of care treatment in elderly women with ovarian cancer: a literature review over the last 10 years","volume":"6","author":"Gibson","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0050","doi-asserted-by":"crossref","first-page":"677","DOI":"10.14336\/AD.2017.0607","article-title":"Ovarian cancer management in the oldest old: improving outcomes and tailoring treatments","volume":"8","author":"Tortorella","year":"2017","journal-title":"Aging Dis."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0055","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ygyno.2005.04.037","article-title":"Treatment patterns by decade of life in elderly women (\u226570 years of age) with ovarian cancer","volume":"98","author":"Uyar","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0060","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jamaoncol.2021.0696","article-title":"Efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian cancer: a GINECO\/GCIG randomized clinical trial","volume":"7","author":"Falandry","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0065","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ygyno.2018.02.017","article-title":"Treatment and outcome of elderly patients with advanced stage ovarian cancer: a nationwide analysis","volume":"149","author":"Schuurman","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0070","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0075","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","article-title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): results from a double-blind, phase 3, randomised controlled trial","volume":"19","author":"Oza","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0080","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2018.12.009","article-title":"Efficacy and safety of niraparib as maintenance treatment in older patients (\u226570 years) with recurrent ovarian cancer: results from the ENGOT-OV16\/NOVA trial","volume":"152","author":"Fabbro","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0085","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer, N","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0090","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ygyno.2020.05.045","article-title":"The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: a post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma","volume":"159","author":"Colombo","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0095","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejca.2022.11.029","article-title":"Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged >\/=65 years from the PAOLA-1\/ENGOT-ov25 trial","volume":"181","author":"Sabatier","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0100","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/IGC.0000000000001221","article-title":"Safety and efficacy of extended bevacizumab therapy in elderly (>\/=70 years) versus younger patients treated for newly diagnosed ovarian cancer in the international ROSiA study","volume":"28","author":"Selle","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2016.11.006","article-title":"Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: subgroup analysis of the randomised phase III AURELIA trial","volume":"144","author":"Sorio","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2022.01.024","article-title":"Efficacy and safety of olaparib according to age in BRCA1\/2-mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2\/ENGOT-Ov21 study","volume":"165","author":"Trillsch","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0120","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0895-4356(96)00428-3","article-title":"Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement","volume":"50","author":"Groenvold","year":"1997","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0125","author":"European Organisation for Research and Treatment of Cancer"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0130","series-title":"The EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0135","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0140","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer","volume":"39","author":"Greimel","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0150","doi-asserted-by":"crossref","first-page":"16021","DOI":"10.1200\/jco.2007.25.18_suppl.16021","article-title":"Validation of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Symptom Index (FOSI) in a phase II clinical trial of pertuzumab in patients with advanced ovarian cancer","volume":"25","author":"Beaumont","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0160","first-page":"1727","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"QoL Res."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0165","author":"EuroQol Research Foundation"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0170","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ygyno.2024.01.021","article-title":"Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: results from the phase 3 randomized PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"184","author":"Pothuri","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0175","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/curroncol29010029","article-title":"Safety profile of niraparib as maintenance therapy for ovarian cancer: a systematic review and meta-analysis","volume":"29","author":"Pagkali","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0180","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/cncr.34706","article-title":"Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"129","author":"Mirza","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0185","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ygyno.2017.10.007","article-title":"Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer","volume":"147","author":"Dockery","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0190","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/annonc\/mdl401","article-title":"Feasibility, toxicity and quality of life of first-line chemotherapy with platinum\/paclitaxel in elderly patients aged > or =70 years with advanced ovarian cancer\u2014a study by the AGO OVAR Germany","volume":"18","author":"Hilpert","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0195","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1200\/JCO.2020.38.15_suppl.6068","article-title":"Efficacy and safety of olaparib according to age in BRCA-1\/2 mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2 (AGO-OVAR 2.23\/ENGOT-Ov21) study","volume":"38","author":"Trillsch","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0200","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4321\/S1886-36552014000400007","article-title":"Defining 'elderly' in clinical practice guidelines for pharmacotherapy","volume":"12","author":"Singh","year":"2014","journal-title":"Pharm. Pract. (Granada)"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051295","article-title":"Multi-disciplinary care planning of ovarian cancer in older patients: general statement-a position paper from SOFOG-GINECO-FRANCOGYN-SFPO","volume":"14","author":"Bengrine","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2024.03.009_bb0210","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ygyno.2017.07.126","article-title":"Functional not chronologic age: frailty index predicts outcomes in advanced ovarian cancer","volume":"147","author":"Kumar","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0215","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1093\/annonc\/mdt360","article-title":"Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial","volume":"24","author":"Falandry","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.009_bb0220","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2017.11.013","article-title":"Alterations in comprehensive geriatric assessment decrease survival of elderly patients with cancer","volume":"90","author":"Frasca","year":"2018","journal-title":"Eur. J. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T13:41:30Z","timestamp":1745329290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824001549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":42,"alternative-id":["S0090825824001549"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.03.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of niraparib in patients aged 65\u00a0years and older with advanced ovarian cancer: Results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}